Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocaperidone is an experimental benzisoxazol piperidine antipsychotic drug. It primarily acts as a potent antagonist at serotonin 5-HT2 receptors and dopamine D2 receptors, and also functions as a 5-HT1A agonist. The compound exhibits high affinity for these targets (Kis of approximately 0.14 nM for 5-HT2, 0.46 nM for D2, and 0.75 nM for 5-HT1A). Its mechanism of action suggests potential use in the treatment of psychiatric disorders such as schizophrenia and other psychoses by modulating serotonergic and dopaminergic neurotransmission[6][10]. Ocaperidone has been studied in various formulations suitable for oral, buccal/sublingual, parenteral (injection), and rectal administration[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ocaperidone.